{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:44:53Z","timestamp":1773409493798,"version":"3.50.1"},"reference-count":31,"publisher":"Japan Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1507\/endocrj.ej14-0393","type":"journal-article","created":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T23:54:31Z","timestamp":1411602871000},"page":"13-20","source":"Crossref","is-referenced-by-count":17,"title":["Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients"],"prefix":"10.1507","volume":"62","author":[{"given":"Wakaba","family":"Tsuchimochi","sequence":"first","affiliation":[{"name":"Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ueno","sequence":"additional","affiliation":[{"name":"Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichiro","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Tsubouchi","sequence":"additional","affiliation":[{"name":"Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Sakoda","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disease, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan"},{"name":"Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Heiwadai Hospital, Miyazaki 880-0034, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Nakazato","sequence":"additional","affiliation":[{"name":"Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H<i>, et al.<\/i> (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. <i>Nature<\/i> 402: 656-660.","DOI":"10.1038\/45230"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tsch&oumlp M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. <i>Nature<\/i> 407: 908-913.","DOI":"10.1038\/35038090"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H<i>, et al.<\/i> (2001) A role for ghrelin in the central regulation of feeding. <i>Nature<\/i> 409: 194-198.","DOI":"10.1038\/35051587"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Heppner KM, Tong J (2014) Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions. <i>Eur J Endocrinol<\/i> 171: R21-32.","DOI":"10.1530\/EJE-14-0183"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Todd JF, Bloom SR (2007) Incretins and other peptides in the treatment of diabetes. <i>Diabet Med<\/i> 24: 223-232.","DOI":"10.1111\/j.1464-5491.2006.02071.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Seino Y, Fukushima M, Yabe D (2010) GIP and GLP-1, the two incretin hormones: Similarities and differences. <i>J Diabetes Investig<\/i> 22: 8-23.","DOI":"10.1111\/j.2040-1124.2010.00022.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Pala L, Ciani S, Dicembrini I, Bardini G, Cresci B<i>, et al.<\/i> (2010) Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions. <i>Diabet Med<\/i> 27: 691-695.","DOI":"10.1111\/j.1464-5491.2010.03010.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Deacon CF, Holst JJ (2009) Immunoassays for the incretin hormones GIP and GLP-1. <i>Best Pract Res Clin Endocrinol Metab<\/i> 23: 425-432.","DOI":"10.1016\/j.beem.2009.03.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yabe D, Watanabe K, Sugawara K, Kuwata H, Kitamoto Y<i>, et al.<\/i> (2012) Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patientes with type 2 diabetes. <i>J Diabetes Investig<\/i> 3: 70-79.","DOI":"10.1111\/j.2040-1124.2011.00141.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Goda M, Kadowaki T (2013) Teneligliptin for the treatment of type 2 diabetes. <i>Drugs Today (Barc)<\/i> 49: 615-629.","DOI":"10.1358\/dot.2013.49.10.2035882"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Marling CR, Shubrook JH, Vernier SJ, Wiley MT, Schwartz FL (2011) Characterizing blood glucose variability using new metrics with continuous glucose monitoring data. <i>J Diabetes Sci Technol<\/i> 5: 871-878.","DOI":"10.1177\/193229681100500408"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Harano Y, Miyawaki T, Nabiki J, Shibachi M, Adachi T<i>, et al.<\/i> (2006) Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. <i>Endocr J<\/i> 53: 173-180.","DOI":"10.1507\/endocrj.53.173"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kadowaki T, Kondo K (2013) Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. <i>Diabetes Obes Metab<\/i> 15: 810-818.","DOI":"10.1111\/dom.12092"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Akamizu T, Sakura N, Shigematsu Y, Tajima G, Ohtake A<i>, et al.<\/i> (2012) Analysis of plasma ghrelin in patients with medium-chain acyl-CoA dehydrogenase deficiency and glutaric aciduria type II. <i>Eur J Endocrinol<\/i> 166: 235-240.","DOI":"10.1530\/EJE-11-0785"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF<i>, et al.<\/i> (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. <i>Diabetologia<\/i> 28: 412-419.","DOI":"10.1007\/BF00280883"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Onishi Y, Hayashi T, Sato KK, Ogihara T, Kuzuya N<i>, et al.<\/i> (2010) Fasting tests of insulin secretion and sensitivity predict future prediabetes in Japanese with normal glucose tolerance. <i>J Diabetes Investig<\/i> 1: 191-195.","DOI":"10.1111\/j.2040-1124.2010.00041.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB<i>, et al.<\/i> (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care<\/i> 32: 335-341.","DOI":"10.2337\/dc08-1478"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Rijkelijkhuizen JM, Girman CJ, Mari A, Alssema M, Rhodes T<i>, et al.<\/i> (2009) Classical and model-based estimates of beta-cell function during a mixed meal vs. an OGTT in a population-based cohort. <i>Diabetes Res Clin Pract<\/i> 83: 280-288.","DOI":"10.1016\/j.diabres.2008.11.017"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ueno H, Shiiya T, Mizuta M, Mondal SM, Nakazato M (2007) Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. <i>Endocr J<\/i> 54: 895-902.","DOI":"10.1507\/endocrj.K07-007"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Aaboe K, Knop FK, Vilsboll T, Deacon CF, Holst JJ<i>, et al.<\/i> (2010) Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. <i>Diabetes Obes Metab<\/i> 12: 323-333.","DOI":"10.1111\/j.1463-1326.2009.01167.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. He YL, Foteinos G, Neelakantham S, Mattapalli D, Kulmatycki K<i>, et al.<\/i> (2013) Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. <i>Diabetes Obes Metab<\/i> 15: 1111-1119.","DOI":"10.1111\/dom.12146"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Vella A, Bock G, Giesler PD, Burton DB, Serra DB<i>, et al.<\/i> (2007) Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. <i>Diabetes<\/i> 56: 1475-1480.","DOI":"10.2337\/db07-0136"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hsueh WA, Law RE (1999) Insulin signaling in the arterial wall. <i>Am J Cardiol<\/i> 84: 21J-24J.","DOI":"10.1016\/S0002-9149(99)00353-7"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Malek M, Aghili R, Emami Z, Khamseh ME (2013) Risk of cancer in diabetes: The effect of metformin. <i>ISRN Endocrinol<\/i> 2013: 636927.","DOI":"10.1155\/2013\/636927"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y<i>, et al.<\/i> (2013) A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. <i>Biochem Biophys Res Commun<\/i> 434: 191-196.","DOI":"10.1016\/j.bbrc.2013.03.010"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Eto T, Inoue S, Kadowaki T (2012) Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. <i>Diabetes Obes Metab<\/i> 14: 1040-1046.","DOI":"10.1111\/j.1463-1326.2012.01662.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Rizza RA (2010) Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. <i>Diabetes<\/i> 59: 2697-2707.","DOI":"10.2337\/db10-1032"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ahren B, Schweizer A, Dejager S, Dunning BE, Nilsson PM<i>, et al.<\/i> (2009) Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. <i>J Clin Endocrinol Metab<\/i> 94: 1236-1243.","DOI":"10.1210\/jc.2008-2152"},{"key":"29","unstructured":"29. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma <i>in vitro<\/i> yields an N-terminally truncated peptide that is a major endogenous metabolite <i>in vivo<\/i>. <i>J Clin Endocrinol Metab<\/i> 80: 952-957."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Huang CL, Hsu CH, Huang KC, Su HY, Weng SF (2010) Preprandial single oral dose of sitagliptin does not affect circulating ghrelin and gastrin levels in normal subjects. <i>Pharmacology<\/i> 85: 131-135.","DOI":"10.1159\/000280583"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Vella A, Bock G, Giesler PD, Burton DB, Serra DB<i>, et al.<\/i> (2008) The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. <i>Clin Endocrinol (Oxf)<\/i> 69: 737-744.","DOI":"10.1111\/j.1365-2265.2008.03235.x"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T10:46:22Z","timestamp":1565865982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/62\/1\/62_EJ14-0393\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej14-0393","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}